D5242R00010
Open-label Single-arm, Non-interventional, Multi-centre Study for Evaluation of Clinical and Patient Reported Outcomes in Adult Patients With CRSwNP on Tezepelumab
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT07399665/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование идёт, в реестре указано, что набор участников открыт.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 110 чел. во всех странах исследования.
- Плановое окончание — 03.2028.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 10 · невключение: 4
Критерии включения
- Male or female participants aged 18 years or older at the time of signing the ICF.
- Diagnosis of CRSwNP established for at least 52 weeks prior to tezepelumab initiation.
- Availability of participants' medical records for at least 52 weeks prior to tezepelumab initiation, including history of sCS use / nasal polyps surgery (or information about contraindications / intolerance to).
- Prescribed and initiated treatment with tezepelumab according to SmPC and local market reimbursement criteria. A period between treatment initiation and enrolment should be no more than 4 weeks.
- The severity of CRSwNP consistent with need for surgery as defined by total NPS ≥ 5 (at least 2 for each nostril) at the enrollment.
- Nasal Blockage score as part of SNOT-22 (NBS-SNOT-22) ≥ 3 at the enrollment.
- SNOT-22 total score ≥ 30 at enrollment or up to 12 weeks before enrollment.
- Currently receive care from specialist physicians (e.g., otolaryngologist) at the Investigator's or sub-Investigator's site.
- Provision of signed and dated written informed consent.
- Participants are able to read, understand and complete the questionnaires required by the protocol.
Критерии невключения
- Any contraindication to tezepelumab as per the approved product SmPC in Russia or in the opinion of the Investigator.
- Administration of concurrent biologic drug for CRSwNP / asthma since the index date, except for stable allergen immunotherapy (defined as a stable dose and regimen at the time of enrolment). Enrolment of patients who were switched from other biologic(s) to tezepelumab is allowed, and an acceptable timeframe since the last prior biologic drug is ≥ 60 days. The number of participants with prior biologic treatment (switching to tezepelumab) should be targeted at 20% or less.
- Participation in an observational study that might, in the Investigator's opinion, influence the assessment for the current study, or participation in an interventional clinical trial in the last 3 months.
- Pregnancy or lactation period.
Источник: ClinicalTrials.gov, NCT07399665 · запись обновлена в реестре 16 сентября 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (4), вторичных — 31
- 1. Change in endoscopic status of CRSwNP based on NPS — time points to measure: baseline and at Weeks 4, 24 and 52 following tezepelumab initiation
- 2. Change in a nasal congestion status based on Nasal Blockage score as part of SNOT-22 (NBS-SNOT-22) — time points to measure: baseline and at Weeks 4, 24 and 52 following tezepelumab initiation
- 3. Change in endoscopic status of CRSwNP based on NPS — time points to measure: baseline and at Weeks 4, 24 and 52 following tezepelumab initiation
- 4. Change in a nasal congestion status based on Nasal Blockage score as part of SNOT-22 (NBS-SNOT-22) — time points to measure: baseline and at Weeks 4, 24 and 52 following tezepelumab initiation
Цель исследования
ARES is a multi-centre, retrospective-prospective, non-comparative and non-interventional (observational) cohort study involving primary and secondary data collection within real-world settings of participants who have initiated tezepelumab (no more than 4 weeks before inclusion) for treatment of CRSwNP (with or without comorbid asthma).
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07399665 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, набор участников, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.